Leverage Shares 2X Long SNDK Daily ETF

SNDG
2.68028.85% ( +0.600 )
Trading: Nov 11, 15:53:07 (EDT)

Leverage Shares 2X Long SNDK Daily ETF (SNDG)

Open
2.430
High
2.820
Low
2.370
Prev. Close
2.080
Volume
19.70M
Turnover
52.11M
Avg Price
2.645
Bid/Ask Ratio
58.05%
Amplitude
21.63%
52wk High
30.800
Volume Ratio
5.93
Turnover Ratio
166.69%
52wk Low
1.830
Float Mkt Cap
31.68M
Dividend YieldTTM
--
DividendTTM
--
NAV
--
NAV Date
--
Disc/Prem Rate
--
Total Issued
11.82M
Assets
31.68M
Min lot size
1
Currency
USD

News

Bullish vs. Bearish — Last 3 Months

1.8k followers · 0 opinions
▲Bullish50%
50%Bearish▼
  • 云
    云起落

    Oil prices pulled back yesterday, triggering a short squeeze. With too many crowded into shorts on semiconductors, it actually sets up a rebound for the sector and hardware stocks. Trump recently weighed in to clear things up for Jensen Huang, and such rumors are trivial to him. Therefore, I believe the short-term panic surrounding $NVIDIA(NVDA.US) is unlikely to escalate.

    From a technical perspective, $Invesco QQQ Trust(QQQ.US) needs to bounce above 675 and hold support to confirm the trend today (Confirmation). If it breaks through the second key level of 704 tomorrow, our chances of a reversal increase.

    The system still treats this as a "rebound" rather than a "reversal," so overall risk remains high; thus, taking profits is advisable. If 704 is broken with increasing volume, we can gradually add positions. $Micron Tech(MU.US)$Sandisk(SNDK.US) $Lumentum(LITE.US), along with COHR, MRVL, INTC, SOXL, SOXX, AMD, GOOG, and the other seven tech giants, are poised for a sharp rebound.

    Let’s go, let's squeeze those shorts! My account recovered significantly today, feeling good!

  • S
    StockMarket.News

    $Moderna(MRNA.US) is now up more than 840% this year

    Shares jumped another 9% today to a fresh 2026 high near $278, up from $29.49 at the end of 2025

    That's more than 3x the 273% YTD gain of $Sandisk(SNDK.US), another one of the S&P 500's biggest winners of 2026

    Fuel for the run

    The personalized cancer vaccine with $Merck(MRK.US) cut melanoma recurrence or death by 42% in a Phase 3 trial, with a 2027 launch targeted

    Q3 revenue came in at $1.31B vs $885M expected, and EPS was $0.38 vs an expected loss of $1.25

    Full-year revenue growth guidance was raised to 15% to 25%, from up to 10%, which would be the first year of growth since 2022

    Moderna went from a post-Covid cautionary tale to the hottest large-cap in the market in under a year, and it did it with drug data, not AI. With the stock at 9x its January price, every pipeline headline from here moves it hard in both directions

    Source: StockMarket.News

    图片 1,共 1 张